Literature DB >> 20974589

Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery.

Kayi Y Chan1, Michael Baun, René de Vries, Antoon J van den Bogaerdt, Clemens M F Dirven, Alexander H J Danser, Inger Jansen-Olesen, Jes Olesen, Carlos M Villalón, Antoinette MaassenVanDenBrink, Saurabh Gupta.   

Abstract

OBJECTIVE: We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.
METHODS: Concentration response curves to PACAP38, PACAP27, VIP and the VPAC(1) receptor agonist ([Lys15,Arg16,Leu27]-VIP[1-7]-GRF[8-27]) were constructed in the absence or presence of the PAC(1) receptor antagonist PACAP6-38 or the VPAC(1) receptor antagonist, PG97269. mRNA expression was measured using qPCR.
RESULTS: PACAP38 was less potent than VIP in both arteries. Both peptides had lower potency and efficacy in meningeal than in coronary arteries, while mRNA expression of VPAC(1) receptor was more pronounced in meningeal arteries. PACAP6-38 reduced the E(max) of PACAP27, while PG97269 right-shifted the VIP-induced relaxation curve only in the coronary arteries.
CONCLUSION: The direct vasodilatory effect of VIP and PACAP might be less relevant than the central effect of this compound in migraine pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974589     DOI: 10.1177/0333102410375624

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  21 in total

Review 1.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

Review 2.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 3.  Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Authors:  Anne Luise Haulund Vollesen; Faisal Mohammad Amin; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

4.  Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

Authors:  Kristian Agmund Haanes; Lars Edvinsson
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

Review 5.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 6.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

7.  Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds.

Authors:  Gustaf Grände; Sieneke Labruijere; Kristian Agmund Haanes; Antoinette MaassenVanDenBrink; Lars Edvinsson
Journal:  J Headache Pain       Date:  2014-04-23       Impact factor: 7.277

Review 8.  Protective effects of PACAP in ischemia.

Authors:  Dora Reglodi; Alexandra Vaczy; Eloísa Rubio-Beltran; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2018-03-02       Impact factor: 7.277

9.  Pituitary adenylate cyclase-activating polypeptide expression in peripheral blood mononuclear cells of migraineurs.

Authors:  Lei Hou; Dongjun Wan; Zhao Dong; Wenjing Tang; Xun Han; Li Li; Fei Yang; Shengyuan Yu
Journal:  Cell Biosci       Date:  2016-06-10       Impact factor: 7.133

Review 10.  PACAP38 in human models of primary headaches.

Authors:  Håkan Ashina; Song Guo; Anne L H Vollesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2017-11-23       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.